The role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(−/−) mice

Por Moss, Aaron M., Endres, Christopher J., Ruiz-Garcia, Ana, Choi, Doo-Sup, Unadkat, Jashvant D.
Publicado em 2012

The Sas3p and Gcn5p histone acetyltransferases are recruited to similar genes

Por Rosaleny, Lorena E, Ruiz-García, Ana B, García-Martínez, José, Pérez-Ortín, José E, Tordera, Vicente
Publicado em 2007

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results

Por Heath, Elisabeth I., Blumenschein, George R., Cohen, Roger B., LoRusso, Patricia M., LoConte, Noelle K., Kim, Sindy T., Ruiz-Garcia, Ana, Chao, Richard C., Wilding, George
Publicado em 2010

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kina...

Por Takahashi, Toshiaki, Boku, Narikazu, Murakami, Haruyasu, Naito, Tateaki, Tsuya, Asuka, Nakamura, Yukiko, Ono, Akira, Machida, Nozomu, Yamazaki, Kentaro, Watanabe, Junichiro, Ruiz-Garcia, Ana, Imai, Keiji, Ohki, Emiko, Yamamoto, Nobuyuki
Publicado em 2012

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

Por Blais, Normand, Camidge, D. Ross, Jonker, Derek J., Soulières, Denis, Laurie, Scott A., Diab, Sami G., Ruiz-Garcia, Ana, Thall, Aron, Zhang, Ke, Chao, Richard C., Chow, Laura Q.
Publicado em 2013

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

Por Bang, Yung-Jue, Kang, Yoon-Koo, Kang, Won K., Boku, Narikazu, Chung, Hyun C., Chen, Jen-Shi, Doi, Toshihiko, Sun, Yan, Shen, Lin, Qin, Shukui, Ng, Wai-Tong, Tursi, Jennifer M., Lechuga, Maria J., Lu, Dongrui Ray, Ruiz-Garcia, Ana, Sobrero, Alberto
Publicado em 2010

A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer...

Por Reckamp, Karen L., Giaccone, Giuseppe, Camidge, D. Ross, Gadgeel, Shirish M., Khuri, Fadlo R., Engelman, Jeff A., Koczywas, Marianna, Rajan, Arun, Campbell, Alicyn K., Gernhardt, Diana, Ruiz‐Garcia, Ana, Letrent, Stephen, Liang, Jane, Taylor, Ian, O'Connell, Joseph P., Jänne, Pasi A.
Publicado em 2014

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-C...

Por Ramalingam, Suresh S., Blackhall, Fiona, Krzakowski, Maciej, Barrios, Carlos H., Park, Keunchil, Bover, Isabel, Seog Heo, Dae, Rosell, Rafael, Talbot, Denis C., Frank, Richard, Letrent, Stephen P., Ruiz-Garcia, Ana, Taylor, Ian, Liang, Jane Q., Campbell, Alicyn K., O'Connell, Joseph, Boyer, Michael
Publicado no J Clin Oncol (2012)